

Panton-Valentine Leukocidin (PVL) Skin Abscesses in Children and Adolescents Diagnostic and Treatment - A Case Report

Katharina Schulte^{1*} and Rizwan Attia²

¹Department of General and Visceral Surgery, Sana Hospital Berlin, Fanninger Str. 32, 10365 Berlin, Germany

²Department of Cardiothoracic Surgery, Royal Sussex County Hospital, Brighton, BN2 5BE, UK

*Corresponding author

Katharina Schulte, Department of General and Visceral Surgery Sana Hospital Berlin, Germany, Tel: +49 (0) 30 5518 2317; E-mail: katharina.schulte@sana-kl.de

Submitted: 04 Feb 2019; Accepted: 11 Feb 2019; Published: 01 Mar 2019

Summary

Panton–Valentine leukocidin is a cytotoxin, which is associated with an increased virulence of isolates of Staphylococcus aureus. It can cause necrotic dermal lesions or recurrent skin abscesses and in rare cases necrotic haemorrhagic pneumonia.

In our case a 15-year-old immunocompetent male was seen in the emergency department complaining of a painful tibial swelling. He had been travelling to South East Asia a year ago and had been suffering from multiple skin abscesses since then. Clinically, a tibial abscess was diagnosed and operatively excised the same day. The postoperative course of the patients was uneventful. In the microbiological analysis a methicillin-susceptible Staphylococcus aureus was isolated and the presence of lukF-lukS genes for Panton–Valentine leukocidin was determined. In order to avoid further spread of the cytotoxin the patient underwent an ambulant antibiotic eradication therapy with Cotrimoxazole 960mg twice daily for 5 days along with a decolonisation.

An infection with Panton–Valentine leukocidin should be suspected diagnosed and treated in young immunocompetent patients with recurrent cutaneous abscesses or affected contacts.

Keywords: Panton–Valentine Leukocidin (PVL) - Complication–Skin Abscesses - Staphylococcus Aureus – Methicillin Resistant Staphylococcus Aureus (MRSA) – Methicillin Susceptible Staphylococcus Aureus (MSSA)

Abbreviations

PVL: Panton–Valentine Leukocidin

HA-MRSA: Healthcare-Associated MRSA

CA-MRSA: Community-Acquired MRSA

MSSA: Methicillin-Susceptible Staphylococcus Aureus

Introduction

Panton–Valentine leukocidin (PVL) is a cytotoxin, which is associated with increased virulence of Staphylococcus aureus resulting in necrotic dermal lesions, cutaneous abscesses, and furunculosis and in rare case necrotic haemorrhagic pneumonia [1]. It is present in the majority of community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates and is associated with an increased virulence of methicillin-susceptible Staphylococcus aureus (MSSA) [2].

Material and Methods

A 15-year-old immunocompetent male was seen in the emergency department complaining of a painful tibial swelling. He had been travelling to South East Asia a year ago and had been suffering from multiple skin abscesses since then. Clinically, a tibial abscess was

diagnosed and excised the same day. The postoperative course of the patients was uneventful. The microbiological analysis showed a MSSA and the presence of lukF-lukS genes for PVL association. In order to avoid further spread the patient underwent an ambulant antibiotic eradication therapy with Cotrimoxazole 960mg twice daily for 5 days along with a decolonisation.

Discussion

MRSA infections are classified as healthcare-associated (HA-MRSA) or community-acquired (CA-MRSA) [3, 4]. CA-MRSA infections are increasingly seen in healthy individuals without any exposure to healthcare facilities and in immunocompetent populations like children and adolescents [5]. CA-MRSA show different antimicrobial profiles than HA-MRSA and are associated with a higher virulence and soft tissue and skin [6-8].

PVL is a cytotoxin made of F and S sub-units which contain lukF-lukS genes [7]. It forms pores exclusively in leukocytes and induces high inflammatory mediators such as leukotriene B₄, IL-8 and histamine [9]. When lukF-lukS genes are positively tested, the diagnosis of PVL infection can be made.

PVL is known to induce furunculosis, cutaneous abscesses, invasive soft tissue infections and necrotising pneumonia [10-12].

Our case highlights the clinical impact and the virulence of PVL

showing the need of an accurate microbiological diagnosis and appropriate drug treatment. This is not only to avoid subsequent recurrences of cutaneous infections but also to prevent further spread and the manifestation of even more serious infections such as necrotising pneumonia.

Increasing awareness among community-based healthcare providers of PVL-producing *Staphylococcus aureus* infections is important to facilitate rapid and adequate response in similar clinical events in the future.

Conclusion

An infection with PVL should be suspected and ruled out in young immunocompetent patients such as young children and adolescents with recurrent cutaneous abscesses or affected contacts. PVL-positive MRSA and MSSA infections are potential threats to public health due to the fast dissemination with high virulence and an antimicrobial resistance.

Known or expected cases (Table 1) should to undergo a protocolised decolonisation to avoid further spread (Table 2). An antibiotic treatment is recommended in patients with severe skin abscesses or complications (Table 3). PVL-positive patients in hospitals should be isolated in single rooms or in cohorts.

Table 1: Indications for decolonisation

Indications for decolonisation
PVL positive (symptomatic or asymptomatic)
Symptomatic without confirmation of PVL, if PVL positive environment
Asymptomatic without confirmation of PVL, if >2 affected members in the household

Table 2: Protocol of decolonisation

Protocol for decolonisation on five consecutive days
1. Decolonisation of the nose (three times daily)
2. Mouth-Throat-wash (twice daily)
3. Full body wash (once daily)
4. Daily exchange/washing (60 degrees) of clothing/hygienic articles/bed sheets
5. Controls post decolonisation (three days post decolonisation, 3-6 months post decolonisation)
6. Antibiotic treatment of severe skin abscesses or complications

Table 3: Antibiotic regime for patients with severe abscesses

Antibiotic regime for patients with severe/recurrent abscesses
Calculated monotherapy for 5 (up to 14) days
Cotrimoxazole 960mg 1-0-1 p.o.
Clindamycin 600mg 1-1-1 p.o.
Doxycycline 200mg 1-0-0 p.o.
Severe Infections or MRSA+/PVL+ addition with Rifampicin 600mg 1-0-0 p.o. for 3 (up to 14) days

The information received from typing *Staphylococcus aureus* isolates may help within the investigation of nosocomial and community-acquired infections and for the introduction of effective preventive

and infection control measures.

References

- Nubel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, et al. (2008) Frequent emergence and limited geographic dispersal of methicillin-resistant *Staphylococcus aureus*. *Proc Natl Acad Sci USA* 105: 14130-14135.
- Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, et al. (2003) Community-acquired methicillin-resistant *Staphylococcus aureus* carrying Panton–Valentine leukocidin genes: worldwide emergence. *Emerg Infect Dis* 9: 978-984.
- De Sousa MA, De Lencastre H (2003) Evolution of sporadic isolates of methicillin-resistant *Staphylococcus aureus* (MRSA) in hospitals and their similarities to isolates of community-acquired MRSA. *J Clin Microbiol* 41: 3806-3815.
- Saiman L, Keefe MO, Graham PL, Wu F, Saïd-Salim B, et al. (2003) Hospital transmission of community-acquired methicillin-resistant *Staphylococcus aureus* among postpartum women. *Clin Infect Dis* 37: 1313-1319.
- Karchmer AW, Archer GL, Dismukes WE (1983) *Staphylococcus epidermidis* causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. *Ann of Intern Med* 98: 447-455.
- Valle DL, Paclibare PAP, Cabrera EC, Windell L Rivera (2016) Molecular and phenotypic characterization of methicillin-resistant *Staphylococcus aureus* isolates from a tertiary hospital in the Philippines. *Tropical Medicine and Health* 44: 3.
- González-Domínguez M, Seral C, Sáenz Y, Salvo S, Gude MJ, et al. Epidemiological features, resistance genes, and clones among community-onset methicillin-resistant *Staphylococcus aureus* (CO-MRSA) isolates detected in northern Spain. *Int J Med Microbiol* 302: 320-326.
- Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, et al. (1999) Involvement of Panton-Valentine leukocidin—producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis* 29: 1128-1132.
- Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J (1999) Leukocidal toxins of staphylococci. *Zentralbl Bakteriol* 289: 185-201.
- Montgomery CP, Daum RS (2009) Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant *Staphylococcus aureus*: a role for Panton-Valentine leukocidin? *Infect Immun* 77: 2159-2167.
- Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, et al. (2005) A clone of methicillin-resistant *Staphylococcus aureus* among professional football players. *N Engl J Med* 352: 468-475.
- Genestier AL, Michallet MC, Prévost G, Bellot G, Chalabreysse L, et al. (2005) *Staphylococcus aureus* Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. *J Clin Invest* 115: 3117-3127.

Copyright: ©2019 Katharina Schulte. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.